<DOC>
	<DOCNO>NCT01788150</DOCNO>
	<brief_summary>A prospective , randomize , active-control , multi-center clinical trial compare safety efficacy Svelte Drug-Eluting Coronary Stent Integrated Delivery System ( IDS ) commercially available Resolute IntegrityTM Drug-Eluting Stent . The study objective ass safety efficacy Svelte Drug-Eluting Coronary Stent Integrated Delivery System ( IDS ) compare Resolute IntegrityTM Drug-Eluting Stent patient single , never previously treat coronary artery lesion</brief_summary>
	<brief_title>Safety Efficacy Study Svelte Drug-Eluting Coronary Stent Delivery System</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General Inclusion Criteria 1 . Patient ≥18 year old ; 2 . Patient eligible percutaneous coronary intervention ( PCI ) ; 3 . Patient acceptable candidate emergent coronary artery bypass graft ( CABG ) surgery ; 4 . Patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study ; 5 . Female subject childbearing potential must negative pregnancy test within 7days trial procedure ; 6 . Patient subject 's legal representative inform nature trial agrees provision provide write informed consent approve Hospital Research Ethics Committee ( HREC ) respective investigational site ; 7 . Patient agree comply specify followup evaluation return investigational site procedure perform . Angiographic Inclusion Criteria 1 . Patient either single target lesion , two lesion ( target nontarget ) locate separate coronary artery ; 2 . If nontarget lesion treat , must treat first commercially available PTCA balloon and/or stent . Post PCI nontarget vessel , follow condition must meet : 1 . Residual diameter stenosis &lt; 30 % ; 2 . Absence angiographic complication ; 3 . Absence ischemic symptom ; 4 . Absence significant new arrhythmia ECG monitoring change suggestive ischemia . 3 . Reference vessel ≥ 2.5 mm ≤ 3.5 mm diameter visual estimate ; 4 . Target lesion &lt; 20 mm length visual estimate ( intention cover entire lesion one stent adequate length ) ; 5 . Target lesion stenosis ≥ 50 % &lt; 100 % visual estimate . General Exclusion Criteria 1 . Patient currently enrol another investigational device drug trial complete primary endpoint clinically interfere current study endpoint Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial ; 2 . The patient require staged procedure target vessel within 6months staged procedure nontarget vessel within 30days postprocedure ; 3 . The target lesion require treatment device PTCA prior stent placement ( , limit , directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) ; 4 . Any DES deployment anywhere target vessel within past 9months ; 5 . Any BMS deployment anywhere target vessel within past 6months ; 6 . Any previous stent placement within 10 mm ( proximal distal ) target lesion ; 7 . Myocardial infarction within 72hours index procedure , exception : 1 . Patients STEMI PCI culprit lesion may include suitable lesion another vessel , clinically hemodynamically stable 72hours ; 2 . Patients nonSTEMI may include troponin level within laboratory normal range within 24hours preprocedure . 8 . Comorbid condition ( ) could limit patient 's ability participate trial comply followup requirement , impact scientific integrity trial ; 9 . Concurrent medical condition life expectancy le 12months ; 10 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % ; 11 . Unstable angina pectoris extracardiac cause ( Braunwald Class A IIII ) ; 12 . Known allergy follow : Acetylsalicylic acid ( ASA ) , Clopidogrel bisulfate , Ticlopidine , Prasugrel , Rapamycin , Zotarolimus , PEAIII AcBz , Heparin/ Bivalirudin , contrast agent ( adequately premedicated ) ; 13 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3.000 cells/mm3 hemoglobin &lt; 100g/l ; 14 . Acute chronic renal dysfunction ( serum creatinine &gt; 170μmol/L ) ; 15 . History stroke transient ischemic attack ( TIA ) within prior 6months ; 16 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6months ; 17 . History bleed diathesis coagulopathy refuse blood transfusion ; 18 . Patients require ongoing anticoagulation warfarin dabigatran . Angiographic Exclusion Criteria 1 . Total occlusion ( TIMI 0 1 ) ; 2 . Target vessel angiographic evidence thrombus 3 . Target vessel excessively tortuous heavy calcification ; 4 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede run ; 5 . Target lesion locate supply arterial venous bypass graft ; 6 . Ostial target lesion ( within 5.0 mm vessel origin ) location within leave main coronary artery ; 7 . Target lesion involves side branch &gt; 2.0 mm diameter ; 8 . Unprotected Left Main coronary disease ( stenosis &gt; 50 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>